Featured Stories
Infected With Enthusiasm – Evolution of the Serbian Pharma Market
Medis is one of the fastest-growing pharmaceutical companies in Serbia. We talked to the Country Manager, Elina Markovic.
Read More
Country in Focus: Serbia
The total value of the pharmaceutical market in Serbia is € 833 million and it is estimated that it will grow by 6.7% from 2019 to 2021.
Read More
We Maintain the Best Balance Between Development and Risk
Interview with Erna Slana, Managing Director of the Finance and Accounting Division at Medis.
Read More
Medis Proudly Announces a New Partnership with Biocodex Nordics
Exclusive distribution agreement for Medis’ latest development Ladiva, which will be commercialized by Biocodex Nordics in Finland, represents a new important...
Read More
Medis Received the Platinum Creditworthiness Certificate of Excellence for 2020
The Bisnode Analytics Services has ranked Medis among the 1.5% of the most successful, reliable, credible and low-risk companies for cooperation with other...
Read More
A new partnership with Neurim Pharmaceuticals Ltd.
Our exclusive distribution agreement for the commercialization of Slenyto® represents an important milestone for both companies.
Read More